163562-15-0

Basic information

• Product Name: 3H-Benz[e]indole-1-carboxaldehyde, 8-(dipropylamino)-6,7,8,9-tetrahydro-
• CAS NO: 163562-15-0
• Molecular Formula: C19H26N2O
• Molecular Weight: 298.428
• Mol File: 163562-15-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3H-Benz[e]indole-1-carboxaldehyde, 8-(dipropylamino)-6,7,8,9-tetrahydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-Benz[e]indole-1-carboxaldehyde, 8-(dipropylamino)-6,7,8,9-tetrahydro-(163562-15-0)
• EPA Substance Registry System: 3H-Benz[e]indole-1-carboxaldehyde, 8-(dipropylamino)-6,7,8,9-tetrahydro-(163562-15-0)

Safety Data

• Hazardous Substances Data: 163562-15-0(Hazardous Substances Data)

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 83343-44-6 6,7,8,9-tetrahydro-N,N-dipropyl-3H-benz[e]indol-8-amine 
• 83343-37-7 7-amino-2-N,N-dipropylamino-1,2,3,4-tetrahydronaphthalene 
• 83343-42-4 6,7,8,9-tetrahydro-8-(dipropylamino)-3H-benzindole-1,2-dione 
• 136905-98-1 8-chloro-2-(N-n-propyl-N-propionyl-amino)-1,2,3,4-tetrahydronaphthalene 
• 136906-01-9 7-amino-8-chloro-2-(N-n-propyl-N-propionylamino)tetralin 
• 82302-27-0 8-chloro-3,4-dihydro-2(1H)-naphthalenone 
• 2444-36-2 2'-chloro-benzeneacetic acid 
• 51512-09-5 2-(2-chlorophenyl)acetyl chloride 
• 136906-00-8 8-chloro-7-nitro-2-(n-propyl-N-propionylamino)-1,2,3,4-tetrahydronaphthalene 

Relevant articles and documents

Centrally acting 6,7,8,9-tetrahydro-3H-benz(E)indole heterocyclics

A compound of Formula I STR1 or pharmaceutically acceptable salts of Formula I, where R1 is H, C1 -C3 alkyl, --(CH2)n CONH2 where n is 2 to 6, (CH2)n -1-(4,4-dimethylpiperidine-2

(S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1- carbaldehyde: A new class of orally active 5-HT(1A)-receptor agonists

The enantiomers of 6,7,8,9-tetrahydro-N,N-di-n-propyl-3H-benz[e]indol-8- amine (S-(-)-2b and R-(+)-2b) and their corresponding 1-formyl analogs (S-(- )-6 and R-(+)-6 were prepared and evaluated pharmacologically for serotonergic and dopaminergic activity. The introduction of a formyl group in the 1-position shifted the pharmacological profile of 2b from a mixed D2/5- HT(1A) agonists to a selective 5-HT(1A) agonist (6). The enantiomers of 6 were agonists with full intrinsic activity and had an affinity comparable to that of 8-hydroxy-2-(di-n-propylamino)tetrahydronaphthalene (8-OH-DPAT). In contrast to 8-OH-DPAT, the enantiomers of compound 6 were found to have good oral availability.